Key statistics
On Friday, Tevogen Bio Holdings Inc (G28:DEU) closed at 0.354, 0.00% above its 52-week low of 0.354, set on Sep 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.354 |
---|---|
High | 0.354 |
Low | 0.354 |
Bid | 0.354 |
Offer | 0.408 |
Previous close | 0.354 |
Average volume | -- |
---|---|
Shares outstanding | 170.65m |
Free float | 10.19m |
P/E (TTM) | 0.8501 |
Market cap | 54.52m USD |
EPS (TTM) | 0.3758 USD |
Data delayed at least 15 minutes, as of Sep 13 2024.
More ▼
Announcements
- Tevogen Bio Highlights Promising Trial Data as CEO Leads Patient Advocacy at Capitol Hill, Pledging to Leverage Multi-Billion Dollar Company Assets to Combat Long COVID and Spearhead a New Wave of Medical Innovation
- Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation
- Tevogen Bio Secures $6 Million Series C Preferred Stock Investment
- CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares
- Tevogen Bio’s Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health
- Tevogen Bio’s Founding CEO, Ryan Saadi, Expresses Conviction in Company’s Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities
- Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback
- Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian
- Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility
- Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities
More ▼